OmniAb, Inc. (OABIW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 4Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

Market Cap

$44.32M

MomentumView details →

1D Return

+0.98%

YTD Return

+215.79%

RSI (14)

69.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

Market Cap

$44.32M

RSI (14)

69.5

MomentumView details →

1D Return

+0.98%

YTD Return

+215.79%

ProfitabilityView details →

Gross Margin

50.53%

Net Margin

−115.18%

EBITDA Margin

−66.25%

ROE (TTM)

−17.01%

ROA (TTM)

−15.25%

Asset Turnover

0.13x

GrowthView details →

Revenue YoY

+66.89%

EPS YoY

+40.00%

FCF YoY

+43.38%

Revenue CAGR 3Y

−31.89%

EPS CAGR 3Y

+6.56%

EBITDA YoY

+50.32%

EarningsView details →

EPS (Actual)

−$0.05

EPS Surprise

58.33%

Beats (12Q)

2/12

Next Q EPS Est

−$0.13

Avg Surprise (4Q)

17.15%

Rev Surprise

185.85%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

4.80x

Quick Ratio

4.80x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

38.43M

Net Income (TTM)

−44.26M

Op. CF (TTM)

−17.67M

Next earningsNov 17, 2026 →

Latest newsMore news →

OmniAb announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program, leveraging OmniAb's technology platform and expertise in ion channel discovery and screening.19d ago

OmniAb, Inc. reported financial results for the three and six months ended June 30, 2026, and updated its 2026 financial guidance, increasing revenue and cash outlook based on continued business momentum.29d ago

Similar companies

Metagenomi, Inc. Common StockMGX Grace Therapeutics, Inc.GRCE XOMA CorporationXOMAO Veru Inc.VERU Edesa Biotech, Inc.EDSA Genenta Science S.p.A.GNTA Find similar companies →

Latest newsMore news →

OmniAb announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program, leveraging OmniAb's technology platform and expertise in ion channel discovery and screening.19d ago OmniAb, Inc. reported financial results for the three and six months ended June 30, 2026, and updated its 2026 financial guidance, increasing revenue and cash outlook based on continued business momentum.29d ago